Budget impact analysis of the use of extended half-life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspective

Table 8 Scenario analysis

	Overall num. Patients	Num. patients treated with efmoroctocog alfa	Cost CE (Euro)	Cost NE (Euro)	Savings (Euro)	% Savings
Scenario 1	3525	529	755,189,490	736,992,099	18,197,391	2.4%
Scenario 2	4284	474	693,489,851	690,835,256	2,654,595	0.4%

ISSN: 1472-6963